Tiger BioSciences Advances Autologous Wound Care Technology
Tiger BioSciences, a leader in regenerative medicine and tissue innovation, has made a significant advancement in its wound care capabilities. The company recently announced that it has acquired cutting-edge Platelet-Rich Fibrin Matrix (PRFM) technology, along with proprietary PRFM tubes and a unique wound dressing platform from Bahia Medical Inc. This strategic move aims to enhance the company's offerings in autologous wound dressing therapy.
Enhancing the Treatment of Chronic Wounds
The newly integrated PRFM system allows clinicians to prepare high-quality autologous platelet concentrates directly at the point of care. This technology is crucial for treating chronic and complex wounds, which often challenge healthcare providers. The advanced dressing features a versatile design, making it suitable for various wound sizes and capable of serving as a wearable patch that activates PRFM on-site, offering a practical solution for patients and clinicians alike.
Commitment to Innovative Solutions
Oliver Burckhardt, Co-CEO of Tiger BioSciences, expressed enthusiasm about the acquisition, noting that it represents a pivotal moment for the company's efforts to diversify its portfolio. Burckhardt emphasized the alignment of this technology with the company's mission to deliver innovative, first-to-market solutions aimed at empowering clinicians and enhancing patient outcomes.
The addition of the PRFM technology not only expands Tiger BioSciences’ capabilities in regenerative medicine but also signifies the company's commitment to providing a comprehensive suite of solutions tailored to meet varied patient needs across all care settings.
A Forward-Thinking Approach to Wound Care
Garrett Grinsfelder, President of Tiger Wound Care, highlighted the excitement surrounding the incorporation of these technologies into the Tiger BioSciences family. This acquisition is anticipated to enhance the support provided to clinicians, equipping them with advanced and intuitive tools designed to raise the standard of care in wound management.
Tiger BioSciences plans to further develop this newly acquired technology through clinical trials, with aspirations of securing 510(k) clearance from the FDA. The ultimate goal is to see these innovations commercially launched by the end of 2026, marking another chapter in the company's journey of growth and excellence.
About Tiger BioSciences
Tiger BioSciences, headquartered in Conshohocken, PA, is a vertically integrated cell and tissue technology company. It specializes in the recovery, processing, development, and distribution of cellular, acellular, and matrix-like products (CAMPS), alongside aesthetic technologies. With a rich heritage in human cell and tissue processing expertise, Tiger BioSciences operates as a tissue recovery agency and innovator in processing, aesthetics device manufacturing, and as a commercial partner to clinicians. The company is dedicated to delivering state-of-the-art solutions catering to the evolving needs of healthcare providers and their patients, enabling transformative treatment options across a wide range of medical applications. Tiger BioSciences is committed to serving patients, providers, and donor families with integrity and compassion.
Frequently Asked Questions
What is the recent acquisition by Tiger BioSciences?
Tiger BioSciences has acquired Platelet-Rich Fibrin Matrix technology and associated products from Bahia Medical Inc. to enhance its wound care capabilities.
How does the PRFM technology benefit clinicians?
The PRFM technology allows clinicians to prepare high-quality autologous platelet concentrates at the point of care, which is crucial for treating chronic wounds.
What are the goals for the acquired technology?
The goal includes completing clinical trials and pursuing 510(k) clearance with plans for a commercial launch by late 2026.
What does Tiger BioSciences specialize in?
Tiger BioSciences specializes in cellular, acellular, and matrix-like products, as well as aesthetic technologies, focusing on regenerative medicine.
What is the mission of Tiger BioSciences?
The mission is to deliver innovative solutions that empower clinicians and improve patient outcomes through advanced medical technologies.